GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Risk Assessment

Qualis Innovations (Qualis Innovations) Risk Assessment


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Qualis Innovations is: No Data: Cannot be evaluated.

Competitive Comparison of Qualis Innovations's Risk Assessment

For the Medical Devices subindustry, Qualis Innovations's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualis Innovations's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qualis Innovations's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Qualis Innovations's Risk Assessment falls into.


Qualis Innovations  (OTCPK:QLIS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Qualis Innovations Risk Assessment Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualis Innovations (Qualis Innovations) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Risk Assessment
Comparable Companies
VYCO TIVC DYNT BBLG NAOV VTAK INBS NXL THMO ESMC ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Website
https://www.qualisinnovations.com
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751